Pharmacokinetics of Recombinant Alpha A Interferon Following IV Infusion and Bolus, IM, and PO Administrations to African Green Monkeys
- 1 January 1984
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Interferon Research
- Vol. 4 (3), 399-409
- https://doi.org/10.1089/jir.1984.4.399
Abstract
The pharmacokinetics of recombinant alpha A interferon (rIFN- αA) were studied following an intravenous (iv) bolus, 60 min infusion, intramuscular (im), and oral administrations to four African Green monkeys. Each monkey received 3 x 106 units/kg of rIFN-αA parenterally and 6 x 106 units/kg orally. Blood samples were collected and the serum was separated and analyzed for rIFN-α-A concentrations by an enzyme immunoassay, ELISA. No significant changes in clinical chemistry values resulted from rIFN-αA administration. There were no measurable rIFN-αA concentrations (< 20 pg/ml) following oral administration. Serum rIFN-αA concentrations declined rapidly in a biphasic manner following iv bolus and infusion doses and were described by a single pharmacokinetic model. The volume of distribution at steady state (Vdss) ranged from 0.034 to 0.31 l/kg after iv infusion. Total clearance ranged from 4.5 to 19 ml/min, which is about 75% the estimated inulin clearance in monkeys, suggesting glomerular filtration without reabsorption. The elimination half-life ranged from 1.8 to 4.8 h. A prolonged absorption profile was seen following im administration and the systemic bioavailability was 93% when compared with intravenous infusion. The overall disposition of rIFN-αA is comparable to the disposition of other interferons in both animals and humans. The monkey appears to be a suitable pharmacokinetic model for the testing of rIFN-αA and could be useful in conjunction with a viral efficacy model.Keywords
This publication has 20 references indexed in Scilit:
- Antiviral and side effects of interferons produced by recombinant DNA techniques as tested in rhesus monkeysAntiviral Research, 1982
- Model-Independent Steady-State Volume of DistributionJournal of Pharmaceutical Sciences, 1982
- Involvement of the Kidney in Catabolism of Human Leukocyte InterferonJournal of General Virology, 1982
- The Kidney is the Main Site of Interferon DegradationJournal of Interferon Research, 1982
- The Kidney is the Main Site of Interferon CatabolismJournal of Interferon Research, 1982
- Pharmacokinetics of Human Interferon-Beta in MonkeysJournal of Interferon Research, 1981
- Renal Filtration, Absorption and Catabolism of Human Alpha InterferonJournal of Interferon Research, 1981
- Human leukocyte interferon produced by E. coli is biologically activeNature, 1980
- The application of statistical moment theory to the evaluation ofin vivo dissolution time and absorption timeJournal of Pharmacokinetics and Biopharmaceutics, 1980
- Noncompartmental Determination of the Steady‐State Volume of DistributionJournal of Pharmaceutical Sciences, 1979